

Fostemsavir (BMS-663068) Dose-Ranging Study
AI438-006 Study

Fostemsavir (BMS-663068) Dose-Ranging Study AI438-011: Results

GS-US-141-1219: Study Design

- **Background:** Randomized, open-label, multiple-dose, parallel phase IIa study
- **Inclusion Criteria (n = 50)**
 - Adults with subtype B HIV-1
 - Treatment-naïve or experienced,
 - If treatment experienced, off ART ≥8 weeks
 - HIV RNA >5,000 copies/mL
 - CD4 count ≥200 cells/mm³
 - Not pregnant; no hepatitis B or C
 - No prior exposure to an HIV attachment inhibitor
- **Treatment Arms**
 - 8 days of fostemsavir (BMS-663068) +/- ritonavir
 - Participants randomized to various dosing arms

**FOS 600 mg q12h +
RTV 100 mg q12h**
(n = 10)

**FOS 1200 mg qhs +
RTV 100 mg qhs**
(n = 10)


**FOS 1200 mg q12h + RTV
100 mg q12 hrs**
(n = 10)

**FOS 1200 mg q12h + RTV
100 mg qam**
(n = 10)

FOS 1200 mg qhs
(n = 10)

Fostemsavir (BMS-663068) Dose-Ranging Study AI438-011: Results

Baseline to Day 8: Change in Baseline HIV RNA Level



Fostemsavir (BMS-663068) Dose-Ranging Study AI438-011: Conclusions

Interpretation: “Administration of BMS-663068 for 8 days with or without ritonavir resulted in substantial declines in plasma HIV-1 RNA levels and was generally well tolerated. Longer-term clinical trials of BMS-663068 as part of combination antiretroviral therapy are warranted.”

Acknowledgment

The **National HIV Curriculum** is an AIDS Education and Training Center (AETC) Program supported by the Health Resources and Services Administration (HRSA) of the U.S. Department of Health and Human Services (HHS) as part of an award totaling \$800,000 with 0% financed with non-governmental sources. This project is led by the University of Washington's Infectious Diseases Education and Assessment (IDEA) Program.

The content in this presentation are those of the author(s) and do not necessarily represent the official views of, nor an endorsement, by HRSA, HHS, or the U.S. Government.

